Boehringer Ingelheim responds to FDA warning letter
Wireless Pill Bottle Wins Healthcare Innovation World Cup
Phase III results: tiotropium* Respimat® effective in symptomatic asthma patients despite at least ICS†/LABA‡ independent of their age, allergic status, smoking status and bronchodilator response
For Media outside the U.S., Canada and UK
Change in the Board of Managing Directors at Boehringer Ingelheim
ASCO 2013: Boehringer Ingelheim to present highly anticipated new Phase III results for front-runner compounds afatinib* and nintedanib* in first- and second-line NSCLC treatment
